Diabetic retinopathy historical perspective: Difference between revisions

Jump to navigation Jump to search
No edit summary
No edit summary
Line 2: Line 2:
{{Diabetic retinopathy}}
{{Diabetic retinopathy}}
{{CMG}} {{AE}} [[Afsaneh Morteza|Afsaneh Morteza, MD-MPH]] [mailto:afsaneh.morteza@gmail.com]
{{CMG}} {{AE}} [[Afsaneh Morteza|Afsaneh Morteza, MD-MPH]] [mailto:afsaneh.morteza@gmail.com]
{{PleaseHelp}}
==Overview==


==Historical Perspective==
==Historical Perspective==
Line 7: Line 11:


==References==
==References==
{{reflist|2}}
 
{{Reflist|2}}
 
{{WH}}
{{WS}}
[[Category:Needs overview]]
[[Category:Needs content]]
[[Category:Pediatrics]]
[[Category:Endocrinology]]
[[Category:Ophthalmology]]
[[Category:Ophthalmology]]
[[Category:Diabetes]]
[[Category:Blindness]]
[[Category:Endocrinology]]
[[Category:Needs overview]]
{{WikiDoc Help Menu}}
{{WikiDoc Sources}}

Revision as of 13:01, 26 July 2016

Diabetic retinopathy Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Diabetic retinopathy from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

Chest X Ray

CT

MRI

Echocardiography or Ultrasound

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Diabetic retinopathy historical perspective On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Diabetic retinopathy historical perspective

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Diabetic retinopathy historical perspective

CDC on Diabetic retinopathy historical perspective

Diabetic retinopathy historical perspective in the news

Blogs on Diabetic retinopathy historical perspective

Directions to Hospitals Treating Diabetic retinopathy

Risk calculators and risk factors for Diabetic retinopathy historical perspective

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief: Afsaneh Morteza, MD-MPH [2]

Please help WikiDoc by adding content here. It's easy! Click here to learn about editing.

Overview

Historical Perspective

Although diabetes was a well known disease since 2nd AD, no one ever linked this disorder to the eye. In 1946, the french scientist, Appolinaire Bouchardat reported vision loss in the absence of cataract in patients with diabetes. After the introduction of ophthalmoscopes in 1985, Edward Jaeger firstly described the diabetic macular changes in the form of yellowish spots that permeated retina. These observations were challenged as there were no proofs whether macular changes were directly related to diabetes, or they were caused by hypertension and atherosclerosis. The debate continued until the beginning of the 20th century, when Arthur James Ballantyne suggested that diabetic retinopathy represents a unique form of vasculopathy and his work showed for the first time the role of capillary wall alterations in the development of diabetic retinopathy.[1]

References

  1. Wolfensberger TJ, Hamilton AM (2001). "Diabetic retinopathy--an historical review". Semin Ophthalmol. 16 (1): 2–7. PMID 15487691.

Template:WH Template:WS